Appendiceal adenocarcinomas are uncommon, and the genetic alterations present in these tumors are not well characterized. We studied genetic alterations including loss of chromosome 18q (location of DCC, DPC4, and JV-18 genes), and mutations of the DPC4 (SMAD4) and b-catenin genes in 28 appendiceal adenocarcinomas, consisting of 17 mucinous and 11 nonmucinous carcinomas. Chromosome 18q loss was present in 57% (12/21) of appendiceal carcinomas including 54% (7/13) of mucinous and 63% (5/8) of nonmucinous carcinomas. Mutation of the DPC4 gene was present in 14% (three of 22) of the carcinomas occurring in one tumor with chromosome 18q loss and in two with unassessed chromosome 18q status. b-catenin gene mutation was present in 0% (0 of 25) of the carcinomas. Chromosome 18q loss status was not associated with any clinicopathological features. The presence of chromosome 18q loss and DPC4 mutations in appendiceal adenocarcinomas suggests involvement of DPC4 and nearby genes on chromosome 18q (DCC and/or JV-18) in the pathogenesis of appendiceal adenocarcinomas.
Introduction
Appendiceal adenocarcinomas are uncommon, comprising less than 0.4% of all intestinal neoplasms (Lyss, 1988) . These tumors are diagnosed in 0.9-1.4% of appendectomy specimens, and in most cases the diagnosis is made either intraoperatively or postoperatively, rather than preoperatively (McCusker et al., 2002) . The majority of patients with appendiceal carcinoma have mucinous adenocarcinomas, present with pseudomyxoma peritonei, and have protracted disease. In contrast, some patients have nonmucinous or signet ring cell adenocarcinomas and have poor prognosis.
Molecular alterations in the appendiceal carcinomas are not well characterized. We have previously reported that mucinous and nonmucinous appendiceal adenocarcinomas have frequent K-ras mutation like colorectal adenocarcinomas, but they infrequently overexpress p53 and lack microsatellite instability, unlike colorectal adenocarcinomas (Kabbani et al., 2002) .
Chromosome 18q is the chromosomal location of the DCC, DPC4 (SMAD4; MADH4), and JV-18 (SMAD2; MADH2) genes, and loss is frequent in colorectal adenocarcinoma (Thiagalingam et al., 1996) . Status of chromosome 18q has also been shown in previous studies to be an independent prognostic factor in patients with stage II and III colon carcinomas, and tumors without loss are associated with better clinical outcome (Jen et al., 1994; Lanza et al., 1998; Font et al., 2001) .
DPC4 protein is a member of transforming growth factor b (TGFb) family and is involved in signal transduction of the TGFb (reviewed in Shi and Massague´, 2003) . DPC4 is a tumor suppressor gene with frequent alterations in pancreatic adenocarcinomas . Alterations of the DPC4 gene are infrequent (B14%) in colorectal carcinomas and have been variably correlated with prognosis and frequency of metastasis (Lei et al., 1996; Takagi et al., 1996; MacGrogan et al., 1997; Miyaki et al., 1999) . Homozygous deletion or intragenic mutation of one allele with loss of the other allele are the two most common mechanisms involved in inactivation of DPC4 .
Dysregulation of b-catenin signaling due to alterations of the adenomatous polyposis coli gene is an important event in colorectal carcinoma (Sparks et al., 1998) , but b-catenin (CTNNB1) mutations are infrequent in colorectal carcinoma . Altered membranous and nuclear expression of bcatenin by immunohistochemistry has been shown to be associated with prognosis in colorectal carcinoma (Hugh et al., 1999) . Overexpression of b-catenin leads to its translocation to the cell nucleus together with Tcf/ Lef-1, and formation of a bipartite transcriptional factor that activates transcription of many target genes, including c-myc and cyclin D1 .
Chromosome 18q loss, and DPC4 and b-catenin mutations have not been studied in appendiceal carcinoma. In the present study, we studied these molecular alterations in mucinous and nonmucinous adenocarcinoma of appendix and compared them with clinicopathologic features. There were 28 patients with primary appendiceal adenocarcinoma and available formalin-fixed, paraffin-embedded blocks, including 22 patients from a previous study (Kabbani et al., 2002) , and six additional patients with nonmucinous appendiceal adenocarcinomas. The study included 15 women and 13 men with age range of 37-76 years (mean 57711 years). Family history of colorectal or appendiceal carcinoma was absent in all the cases.
Materials and methods

Case material
DNA preparation
Genomic DNA was extracted separately from appendiceal carcinoma and control nonlesional appendiceal or colorectal tissue by microdissection from paraffin-embedded blocks, as described previously (Moskaluk and Kern, 1997).
Microsatellite markers and PCR amplification for chromosome 18q loss status Fluorescent-labeled PCR amplification was performed using microsatellite markers on chromosome 18p (D18S1150) and 18q (centomeric-D18S474, D18S69, D18S64, D18S1147, D18S55, D18S61, D18S58, D18S70-telomeric). Fluorescent dye-labeled and unlabeled primers were obtained (Applied Biosystems, Foster City, CA, USA). The 5 0 oligonucleotide was end-labeled with 6-FAM fluorescent dye. PCR was performed with 40 ng of DNA in a reaction mix consisting of 1 Â GeneAmp PCR Gold buffer (Applied Biosystems, Foster City, CA, USA), 2.5 mM MgCl 2 , 200 mM dNTPs, 0.83 mM of each primer, and 2 U of AmpliTaq Gold DNA polymerase (Applied Biosystems) in a final volume of 15 ml. PCR was performed using a GENEAMP PCR system 9700 (Applied Biosystems) with the following conditions: 951C for 7 min; three cycles of 941C for 1 min, 581C for 30 s, and 721C for 45 s; 42 cycles of 931C for 45 s, 541C for 30 s, 721C for 40 s; and final extension at 721C for 10 min. A 0.25 ml aliquot of each fluorescent-labeled PCR product was analysed on an Applied Biosystems 3700 Genetic Analyzer using GeneScan Analysis software (Applied Biosystems). Each sample included GeneScan 500 (TAMRA) size standard for accurate size calling.
The chromosome 18 loss status was determined from the PCR amplifications of the 10 dinucleotide markers in 21 of 35 tumors with available tumor and control DNA. The ratio of the peak areas of the two alleles from the lesional tissue was compared to the ratio of the peak area of the two alleles from the nonlesional tissue, and only samples showing difference of 50% or more in this ratio were classified as loss of heterozygosity at that microsatellite marker. Continuous and discontinuous deletion of chromosome 18q was ascertained in tumors with loss of more than one microsatellite markers and by no loss or loss of an intervening marker. These results were verified by reamplification.
DNA sequencing of exons 8-11 of DPC4, and exon 3 of b-catenin genes Exons 8-11 of the DPC gene, and exon 3 of the b-catenin gene were amplified by PCR using primers as described previously (Hahn et al., 1998; Rashid et al., 2001) . PCR reaction was performed in a 50 ml volume using buffer (Applied Biosystems) and 1 mM of 5 0 and 3 0 primers. The cycling conditions were: initial denaturation at 951C for 5 min; 40 cycles at 941C for 1 min, 581C for 1 min, and 721C for 2 min; and a final extension cycle at 721C for 10 min. The PCR products were treated with shrimp alkaline phosphatase and exonuclease I (United States Biochemical, Cleveland, OH, USA) and sequenced using the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) with primers used for amplification. The sequence reactions were run on an Applied Biosystems 3700 Genetic Analyzer (Applied Biosystems). The data were collected and analysed using Applied Biosystems sequencing analysis software (Applied Biosystems), according to the manufacturer's protocols. Each mutation was verified by sequencing in both directions and by reamplification by PCR and sequencing.
Statistical analysis
The clinicopathological associations were compared to histological type of carcinomas and status of genetic alterations using w 2 or Fisher's exact test for frequencies, and nonpaired ttest for means using SPSS for Windows software (SPSS Inc., Chicago, IL, USA).
Results
The genetic alterations in appendiceal adenocarcinomas are summarized in Figure 1 .
Chromosome 18 loss and DPC4 gene mutations
Allelic loss of chromosome 18q was present in 57% (12/21) of appendiceal adenocarcinomas including 54% (7/13) of mucinous and 63% (5/8) of nonmucinous carcinomas (examples in Figure 2 and details of microsatellite marker in Table 1 ). By contrast, loss of chromosome 18p occurred in only 9% (1/11) of carcinomas using only one microsatellite marker (P ¼ 0.005), and no tumor had loss of all evaluable 18q markers. Two discrete areas of chromosome 18 loss were present, one centromeric around markers D18S474, D18S69, and D18S64 (18q21.1-21.32) and another telomeric around D18S55, D18S61, and D18S58 (18q22.1-23). All but one tumor with polymorphic alleles retained a marker intermediate to the region 18q21.32-18q21.33 (D18S1147). In all, 88% (seven of eight) tumors with Chromosome 18q loss in appendiceal cancers D Maru et al loss at more than one microsatellite marker had discontinuous deletion with retention of a marker between deleted markers. DPC4 gene mutations were present in 14% (3/22) of appendiceal adenocarcinomas (Figures 1 and 3 and Table 2 ) including 21% (3/14) of mucinous and 0% (0/8) of nonmucinous tumors (statistically nonsignificant). Chromosome 18q loss and DPC4 mutation were variably associated in 15 tumors analysed for both chromosome 18q loss and DPC4 sequencing: one tumor had chromosome 18q loss and DPC4 mutation, seven had chromosome 18 loss without mutation, and seven had neither loss nor mutation.
Mutations of b-catenin gene
No b-catenin mutation was identified in 25 appendiceal adenocarcinomas.
Associations between genetic alterations and clinicopathological characteristics and among genetic alterations
There were no statistically significant associations between genetic alterations and patient or tumor characteristics (Table 3) .
Discussion
In this study, mucinous and nonmucinous appendiceal carcinomas had frequent chromosome 18q loss, and mucinous carcinomas had infrequent DPC4 gene mutation. Chromosome 18q loss has been reported in a variety of tumors including adenocarcinomas of the colorectum, small intestine, breast, pancreas (mucinous and nonmucinous), and ovary (papillary serous), and squamous carcinomas of the head and neck (Jen et al., 1994; Thiagalingam et al., 1996; Fujii et al., 1997; Lanza et al., 1998; Knuutila et al., 1999; Font et al., 2001; Lassus et al., 2001; Blons et al., 2002) . However, chromosome 18q loss in appendiceal carcinomas has not been extensively studied. We found that 54% of mucinous and 63% of nonmucinous appendiceal adenocarcinomas had 18q loss. In a previous study, allelic loss of chromosome 18q was present in 17% of mucinous tumors of the appendix with pseudomyxoma peritonei and 33% of appendiceal adenomas using only two microsatellites markers at 18q21.32-21.33 and 18q22, respectively (Szyck et al., 1999) . This region shows infrequent loss of heterozygosity in our study.
Among the tumor suppressor genes harbored on chromosome 18q, the most extensively studied are DCC gene localized at 18q21.2 and DPC4 (SMAD4) gene localized at 18q21.1 Lei et al., 1996; Schutte et al., 1996; Takagi et al., 1996; Thiagalingam et al., 1996; MacGrogan et al., 1997; Miyaki et al., 1999) . Alterations of DCC gene are identified not only in colorectal carcinoma (Fearon et al., 1990) , but also in pancreatic, gastric, mammary, and prostatic carcinomas (Deevilee et al., 1991; Hohne et al., 1992; Uchino et al., 1992; Gao et al., 1993) . In contrast, DPC4 gene inactivation occurs in almost half of the pancreatic carcinomas , but alterations are uncommon in other malignancies Powell et al., 1997) .
In our study, chromosome 18q loss in appendiceal carcinomas was frequent in two different regions of the chromosomal arm. The first region was around . A previous study has shown frequent chromosome 18q loss at DPC4 locus in mucinous and poorly differentiated colon carcinoma (Kanazawa et al., 2002) , but in our study there was no association with histopathology. In our study, the second region of allelic loss was present around 18q22.1-23 that is distal to the DCC and DPC4 genes, and suggests loss of a region that encompasses the gene for cadherin 19, type 2 (Kremidiotis et al., 1998). Similar to other cadherins, cadherin 19 is a cell adhesion molecule. However, the exact role of this particular cadherin in tumors, including colorectal and appendiceal carcinomas, is still unknown. Other putative tumor suppressor genes localized immediately distal to DCC and DPC4 at microsatellite locus 18q21.3 (D18S55) are serpins (serine proteinase inhibitors), some of which (maspin) reportedly can suppress tumor growth and spread in mammary carcinoma (Zou et al., 1994) .
Interestingly, a similar frequency of chromosome 18q loss was reported for classical midgut carcinoids (Kyto¨laë t al., 2002) , and for sporadic adenocarcinomas of the small intestine (Bla¨ker et al., 2002) . The high frequency of chromosome 18q loss in appendiceal carcinomas in our study, and the presence of chromosome 18q in appendiceal adenomas and mucinous tumors in a previous study (Szyck et al., 1999) , suggest that the tumor suppressor gene(s) present on chromosome 18q play an important role early in the pathogenesis of appendiceal tumors. However, unlike colorectal carcinomas (Jen et al., 1994; Lanza et al., 1998; Font et al., 2001) our study showed no relation between 18q loss and prognosis of the patients with appendiceal adenocarcinoma. In our study, three carcinomas had DPC4 mutations including two with a missense mutation in exon 8 or 11, and one with a 30 bp deletion involving the stop codon. These mutations were present in the DPC4-Smad interacting site in exon 8 and the conserved transcriptional activation domain in the carboxy terminal region of the DPC4 protein Schutte et al., 1996; Powell et al., 1997; Dai et al., 1998) .
Chromosome 18q loss and DPC4 mutation were infrequently associated in our study, suggesting that target of chromosome 18q deletion may be DPC4 and other nearby genes. Alternatively, DPC4 gene may be Figure 2 Examples of loss of heterozygosity of chromosome 18 in appendiceal carcinomas using fluorescent primers. The markers are indicated at the top. PCR was performed using non-neoplastic DNA (N) and tumor DNA (T). Examples of allelic loss in two appendiceal carcinomas are shown for four markers 
Tumor with DPC4 mutation K Polymorphic, loss of heterozygosity; J polymorphic, no loss; NI, not informative
Chromosome 18q loss in appendiceal cancers D Maru et al inactivated by mechanisms not studied in the present study. Mutations of the amino-terminal region of the DPC4 gene are reported, but are infrequent compared to mutations of the carboxy-terminal region Schutte et al., 1996; Powell et al., 1997; Shi and Massague´, 2003) . Homozygous deletion of the DPC4 gene have been reported in pancreatic carcinomas and rarely in other tumors Schutte et al., 1996; Thiagalingam et al., 1996) , but cannot be determined in primary tumor specimens, due to the presence of non-neoplastic cells, and need xenografts or cell lines. Frequent loss of DPC4 protein has been reported in microsatellite stable tumors, but not in tumors with microsatellite instability and with alterations of transforming growth factor b type II receptor (TGFbRII), suggesting inactivation of TGFb pathway in most colorectal carcinomas (Salovaara et al., 2002) . As the frequency of mutations or homozygous deletions of DPC4 gene in colorectal cancers is relatively low (Thiagalingam et al., 1996) , epigenetic silencing due to methylation is another possible mechanism of DPC4 inactivation. However, CpG methylation of the promoter region of DPC4 was not present in colorectal cancers (Roth et al., 2000) . Inactivation of TGFb pathway by alterations of other members of the TGFb family in appendiceal adenocarcinomas is also a consideration (reviewed in Massague´et al., 2000). However, no microsatellite instability was present in the appendiceal carcinomas in our previous study (Kabbani et al., 2002) , suggesting that alterations in the polyadenine tract of the TGFbRII are unlikely in these tumors. In contrast to colorectal carcinomas that have infrequent b-catenin mutations (Sparks et al., 1998; Morin et al., 1997) , appendiceal carcinomas lacked b-catenin mutations.
Our present study suggests that appendiceal adenocarcinoma has frequent chromosome 18q loss that involves two distant chromosomal regions, infrequent DPC4 mutation, and no b-catenin mutation.
